Medical insurance reimbursement conditions for Apremilast

Apremilast is an oral medication used to treat psoriasis and related arthritis. Although it is not currently available in China, many patients may wish to purchase the drug through overseas channels. For patients who purchase domestically and seek medical insurance reimbursement, the following are the general medical insurance reimbursement conditions that may apply:

1.Confirmed disease: Patients must suffer from inflammatory diseases such as psoriasis or related arthritis and be diagnosed by a professional doctor.

2.Prescription drugs: Apremilast is a prescription drug, so patients need to have a valid prescription issued by a professional doctor.

3.Coverage of medical insurance catalog: The drugs purchased by patients need to be covered by the medical insurance catalog before they can enjoy medical insurance reimbursement. However, since Apremilast has not yet been launched in China, patients need to purchase it through overseas channels, so they cannot use medical insurance. There are Apremilast original drugs and generic drugs abroad. The original drugs are mainly European versions of the original drugs, and the price is relatively high, about more than 10,000 yuan. The second cheaper one is the generic version of Apremilast, mainly the Indian version and the Lao version. The price is only about two to three hundred yuan, and the ingredients are basically the same as the original drug.

Although medical insurance reimbursement can greatly reduce patients' drug cost burden, medical insurance reimbursement may face some challenges for patients who purchase overseas drugs. First of all, drugs purchased overseas need to comply with domestic medical insurance policies and regulations before they can enjoy medical insurance reimbursement. Secondly, the medical insurance department may impose certain review requirements on drugs purchased overseas, requiring patients to provide relevant certification materials. Finally, even if eligible for medical insurance reimbursement, patients may still have to bear part of the cost due to the higher price of Apremilast.

In short, although Apremilast has not yet been launched in China and patients cannot purchase it domestically, if patients need to purchase it and seek reimbursement from medical insurance, it is recommended to consult with the relevant departments of the medical insurance department or the hospital to understand the detailed reimbursement policies and procedures. At the same time, patients can also communicate with their doctors to explore other treatment options and drug alternatives to find a more suitable treatment plan.